New Factor XIa Inhibitor Cuts Stroke Risk With Lower Bleeding: Phase III Win
Alex So, Associate Director Strategy and Digitalisation China at Merck Group, posted on LinkedIn:
”Rather than a discouraging attempt that the quoted video may suggest, it is delightful to know the factor XIa inhibitor’s potential to reduce stroke risk in patients who have had a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, as reported by its latest phase III trial for secondary stroke prevention.
Factor XIa can activate Factor IX, amplifying thrombin generation of the clotting process. As an anticoagulation strategy, the inhibition has less impact on clot stabilisation in response to injury, i.e., a lower risk of bleeding. It might be worth rementioning the siRNA drug that silences the gene producing antithrombin, a mechanism in this field applicable to haemophilia as discussed in a prior post.
The milestone success, which enables continued efforts to develop a better blood thinner despite a somewhat reduced scope and to investigate Factor XIa as a target, is encouraging.
Non-business-related therapeutics posting. Consult practitioners for medication needs.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 16:42Kate Grushetzkaya: The Essential Flow Cytometry Checklist – 6 Steps to Better Data
-
Sep 20, 2026, 16:32New Episode of The Hematologist Podcast – ASH
-
Sep 20, 2026, 16:26Thomas Schinecker: A New Era for Health Innovation – Inside the Roche Genentech Innovation Center
-
Sep 20, 2026, 16:19Astha Srivastava: The Missing Megakaryocytes in Amegakaryocytic Thrombocytopenia
-
Sep 20, 2026, 16:19Heghine Khachatryan: An Elegant Example of Precision Thrombolysis – Targeting the Scaffold of Microvascular Thrombosis
-
Sep 20, 2026, 16:01Mohamed Ismail: Managing Extensive Iliofemoral and Inferior Vena Cava DVT
-
Sep 20, 2026, 15:58Can αIIbβ3 Receptor Play a Role in Platelet Production – Glanzmann’s Research Foundation
-
Sep 20, 2026, 15:46Alexsander Santiago: Evaluating Clinical Harm from Missing versus Overdiagnosing HIT
-
Sep 20, 2026, 15:28Nico Gagelmann: iMTSS to Dissect the Drivers of Post-Transplant Outcomes